Orum Therapeutics Gains FDA Clearance for ORM-1153

Boston, Massachusetts, USA, and Daejeon, South Korea, August 22, 2026

FDA Clearance Advances Novel DAC Into Clinical Testing

ORM-1153 is designed using Orum’s TPD²® Dual-Precision Targeted Protein Degradation approach, which combines antibody-based cell targeting with a targeted protein degrader payload. The investigational therapy is designed to selectively deliver a GSPT1 degrader to CD123-expressing cells, enabling degradation of the intracellular GSPT1 protein. This approach is intended to combine the cell-selective delivery capabilities of an antibody with the potential therapeutic effects of targeted protein degradation within cancer cells. According to Orum, the platform is being developed to create cell-selective targeted protein degraders for oncology and other serious diseases. The FDA’s IND clearance represents a key regulatory milestone because it enables Orum to move ORM-1153 into its planned clinical development program. The company described the clearance as an important step toward bringing another potentially first-in-class DAC into the clinic and extending its targeted protein degradation strategy to CD123-expressing hematologic malignancies. However, ORM-1153 remains an investigational therapy, and its safety and efficacy in patients have not yet been established.

Preclinical Data Support ORM-1153 Development

Before entering clinical development, ORM-1153 demonstrated encouraging activity in preclinical AML models. Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 showed broad activity across AML models, including activity in primary AML patient samples and TP53-relevant models. The company also reported low-dose activity in animal studies together with favorable tolerability following repeat dosing. These findings provided preclinical support for advancing ORM-1153 toward a first-in-human study, although results from laboratory and animal models do not establish whether the therapy will demonstrate similar benefits or tolerability in human patients.The scientific rationale behind ORM-1153 is based on targeted delivery and intracellular protein degradation. Orum’s TPD²® platform uses antibody targeting to deliver specially designed degrader payloads to selected cells. Once delivered, the payload is intended to promote degradation of a specific intracellular protein through the E3 ubiquitin ligase pathway. The company believes this approach could provide a highly targeted method for addressing proteins that may be difficult to influence through conventional therapeutic strategies.

Phase 1 Trial to Evaluate Safety and Antitumor Activity

Orum’s planned Phase 1 clinical trial will evaluate the safety and tolerability of ORM-1153 while also assessing its pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. The multicenter study is expected to initially enroll approximately 42 patients at clinical sites in the United States, with the possibility of expanding into additional regions. The study will focus on patients with relapsed or refractory AML and other hematologic malignancies, populations where additional therapeutic approaches remain an important area of clinical research. The planned clinical program represents the next stage in Orum’s development of GSPT1-directed targeted protein degradation therapies. The company expects to use the Phase 1 study to establish an initial clinical safety and pharmacological profile for ORM-1153 and to explore early evidence of antitumor activity. Future development will depend on the results of clinical testing, including safety, enrollment, pharmacokinetic and pharmacodynamic findings, and evidence of therapeutic activity. Orum has cautioned that the expected timing and outcomes of the clinical program remain subject to risks associated with clinical trials, regulatory review, patient enrollment, manufacturing, and development activities.

Source: Orum Therapeutics press relese